axitinib (AK-sih-TIH-nib) is a drug used to treat advanced renal cell carcinoma (the most common type of kidney cancer) .
How does it work?
Axitinib blocks the action of proteins called growth factor receptors and may prevent the growth of new blood vessels that tumors need to grow. It is a type of tyrosine kinase inhibitor and a type of antiangiogenesis agent.
Also called Inlyta.
Information about Axitinib
Axitinib is an oral tyrosine kinase inhibitor selective for vascular endothelial growth factor (VEGF) receptors -1, -2 and -3 that is used in the therapy of advanced renal cell carcinoma.
Background Axitinib (Ax i’ ti nib) is an orally available tyrosine kinase inhibitor with activity against the receptors for vascular endothelial growth factor (VEGF). Engagement of these receptors by VEGF is associated with cell growth and angiogenesis, pathways that stimulate tumor growth. Axitinib also has activity against c-KIT (a tyrosine kinase receptor, mutations of which are found in gastrointestinal stromal tumors) and platelet derived growth factor (PDGF) receptor. Preclinical studies demonstrated that axitinib has activity against several solid tumors in animal models. Clinical trials of axitinib in malignant diseases in humans showed activity against renal cell carcinoma and lesser effects in breast and gastric cancer.
FDA approval information for Axitinib
Axitinib received approval for use in the United States in 2012 for therapy of advanced renal cell carcinoma.
Dosage and administration for Axitinib
Axitinib is available in tablets of 1 and 5 mg under the brand name Inlyta. The typical dose is 5 mg twice daily, which can be increased if well tolerated.
Side effects of Axitinib
- Common side effects include fatigue, diarrhea, hypertension, anorexia, weight loss, nausea, hoarseness, hand-foot syndrome, constipation, arthralgias, abdominal discomfort, headache and rash.
- Uncommon side effects include venous thrombosis and gastrointestinal perforation.
Liver safety of Axitinib
Axitinib therapy is commonly associated with transient elevations in serum aminotransferase that are generally mild and asymptomatic. Axitinib has yet to be linked to instances of clinically apparent acute liver injury.